GX-03 demonstrated clinically meaningful efficacy across a broad spectrum of atopic dermatitis, prompting expansion of the Phase 2 trial to include mild-to-severe patients. The optimized Stage 2 design uses multiple efficacy endpoints and maintains a favorable safety profile.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.